Orum Therapeutics
The role serves as a direct extension of the CEO, independently owning and executing external strategic initiatives to increase Orum's visibility and positioning in the Korean and global biotech sectors. It involves building new capabilities, managing strategic relationships, and delivering market intelligence to support growth.
Headquarters
Lexington, Massachusetts, United States
Company Size
11-50 employees
Founded
2016
Orum Therapeutics is a biotechnology company developing cell‑specific, targeted protein degraders that combine the selectivity of antibody targeting with the mechanism of targeted protein degradation. Their platform aims to selectively eliminate disease‑relevant proteins in defined cell types, expanding the druggable proteome while improving therapeutic precision and safety. Orum advances proprietary degrader therapeutics and works with partners to translate its technology into new treatments.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Orum Therapeutics.
Orum Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Director, Business Operations & Strategy
biolabs
Director / Senior Director, Small Molecule External Innovation
Eli Lilly and Company
Director, Business Development - Biologics (Remote, CA)
Evotec
Business Development Director
Labcorp
CEO & Co-Founder Opportunity | Deeptech BioEngineering | Drug Discovery
Hybride VFX
Director, Regional Ecosystem Lead (Northern Europe & UK)
CSL Behring Australia